Condition
Meniscus Tear: Options and What the Evidence Actually Shows
Not every meniscus tear needs surgery. Degenerative tears in middle age are a different problem than acute athletic tears.
Anatomy and clinical context
Menisci cushion and stabilize the knee. Traumatic tears and degenerative tears behave differently and deserve different counseling.
Physical therapy and watchful waiting help many degenerative tears. Repair is preferred over resection when the tear pattern and tissue quality allow.
Illustration of the human knee joint
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Activity modification and physical therapy for many degenerative tears.
- Step 2
Injections
Limited role for injectates for symptom control; orthobiologics sometimes discussed as adjuncts.
- Step 3
Surgery
Arthroscopic repair or partial meniscectomy when mechanical symptoms persist; meniscal transplant in select cases.
Where cell therapy fits
Meniscus regenerative claims should be read carefully — structural healing is hard to prove, and surgery decisions hinge on tear type and patient goals.
- Degenerative tears often do as well with PT as with arthroscopy in trials of middle-aged patients.
- Same-day cell products are not a substitute for repair when repair is indicated.
- Banking preserves optionality for OA that often coexists with meniscal disease.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.